is indicated for the treatment of individuals with moderate to severe
infections caused by susceptible strains of microorganisms in the specific
conditions listed below:
Mycobacterium tuberculosis: The Advisory Council for the Elimination of
Tuberculosis, the American Thoracic Society, and the Center for Disease Control
recommend that either streptomycin or ethambutol be added as a fourth drug in a
regimen containing isoniazid (INH), rifampin and pyrazinamide for initial
treatment of tuberculosis unless the likelihood of INH or rifampin resistance
is very low. The need for a fourth drug should be reassessed when the results
of susceptibility testing are known. In the past when the national rate of
primary drug resistance to isoniazid was known to be less than 4% and was
either stable or declining, therapy with two and three drug regimens was
considered adequate. If community rates of INH resistance are currently less
than 4%, an initial treatment regimen with less than four drugs may be considered.
is also indicated for therapy of tuberculosis when one or more of the above
drugs is contraindicated because of toxicity or intolerance. The management of
tuberculosis has become more complex as a consequence of increasing rates of
drug resistance and concomitant HIV infection. Additional consultation from
experts in the treatment of tuberculosis may be desirable in those settings.
Non-tuberculosis infections: The use of streptomycin should be limited to the
treatment of infections caused by bacteria which have been shown to be
susceptible to the antibacterial effects of streptomycin and which are not
amenable to therapy with less potentially toxic agents.
granulomatis (donovanosis, granuloma inguinale),
influenzae (in respiratory, endocardial, and meningeal infections–concomitantly
with another antibacterial agent),
pneumoniae pneumonia (concomitantly with another antibacterial agent),
Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary
viridans, Enterococcus faecalis (in endocardial infections–concomitantly with
bacillary bacteremia (concomitantly with another antibacterial agent).
If you are a distributor, please inquire with us about product registration, importing and/or marketing our products in your country or region.
If you are a consumer, don't hesitate to contact us about more information for this product.
Product Categories : Finished Pharmaceutical Products > Tuberculosis